Tirofiban: A critical reappraisal of the clinical use, recent developments and future perspectives

Future Cardiology

Volumn 2, Issue 1, 2006, Pages 17-27

  Valgimigli, Marco ^a,b   Campo, Gianluca ^a,c   Percoco, Gianfranco ^a,c   Pellegrino, Luca ^a,c   Guardigli, Gabriele ^a,c   Ferrari, Roberto ^a,c  

^a UNIVERSITY OF FERRARA   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c IRCCS   (Italy)

Author keywords

Acute coronary syndromes; GPIIb IIIa inhibitors; High dose bolus; Intervention; Percutaneous coronary; Platelet reactivity; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; PYRIDINE DERIVATIVE; RAPAMYCIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BOLUS INJECTION; CARDIOVASCULAR DISEASE; CATHETERIZATION; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; EUROPE; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RECEPTOR AFFINITY; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; UNITED STATES;

EID: 33646546332     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.1.17     Document Type: Article

References (25)

1. Kabbant SS, Watkins MW, Ashikaga T et al.: Platelet reactivity characterized prospectively. A determinant of outcome 90 days after percutaneous coronary intervention. Circulation 104, 181-186 (2001).
2. Kabbant SS, Watkins MW, Ashikaga T, Terrien EF, Sobel BE, Schneider DJ: Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am. J. Cardiol. 91, 876-878 (2003).
3. Matetzky S, Shenkman B, Guetta V et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109, 3171-3175 (2004).
4. Topol EJ, Byzova TV, Plow EF: Platelet GPIIb-IIIa blockers. Lancet 353, 227-231 (1999).
5. Schror K, Weber AA: Comparative Pharmacology of GP IIb/IIIa antagonists. J. Thrombosis Thrombolysis 15(2), 71-80 (2003).
6. The PRISM study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N. Engl. J. Med. 338, 1498-1505 (1998).
7. The PRISM PLUS Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N. Engl. J. Med. 338, 1488-1497 (1998).
8. The RESTORE Investigators: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Cirrulation 96, 1445-1453 (1997).
9. Topol E, Moliterno D, Herrmann H et al.: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. 344, 1888-1894 (2001).
10. Roffi M, Chew DP, Mukherjee D et al.: Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 104, 2767-2771 (2004).
11. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).
12. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur. Heart J. 23, 1809-1840 (2002).
13. Steinhubl SR, Talley JD, Braden GA et al.: Point-of-Care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) Multicenter Study. Circulation 103, 2572-2578 (2001).
14. Stone GW, Moliterno DJ, Bertrand M et al.: Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. Circulation 105(20), 2347-2354 (2002).
15. Bonz AW, Lengenfelder B, Strotmann J et al.: Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR Trial). J. Am. Coll. Cardiol. 40, 662-668 (2002).
16. Batchelor WB, Tolleson TR, Huang Y et al.: Randomized COMparison of Platelet inhibition with Abciximab, tiRofiban and Eptifitbatide during percutaneous coronary intervention in acute coronary syndromes. The COMPARE Trial. Circulation 106, 1470-1476 (2002).
17. Schneider DJ, Herrmann HC, Lakkis N et al.: Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am. J. Cardiol. 90, 1421-1423 (2002).
18. Danzi GB, Capuano C, Sesana M, Baglini R: Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention. Curr. Med. Res. Opin. 19, 28-33 (2003).
19. Valgimigli M, Percoco G, Barbieri D et al.: The additive value of tirofiban administered with the high dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J. Am. Coll. Cardiol. 44, 14-19 (2004).
20. Danzi GB, Sesana M, Capuano C, Mauri L, Berra Centurini P, Baglini R. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am. J. Cardiol. 94, 35-39 (2004).
21. Ernst N, Suryapranata H, Miedema K et al.: Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 44, 1187-1193 (2004).
22. van't Hof AWJ, Ernst N, de Boer M et al.: Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur. Heart. J. 25, 837-846 (2004).
23. Valgimigli M, Percoco G, Malagutti P et al.: STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs. abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293, 2109-2117 (2005).
24. Cannon CP, Weintraub WS, Demopoulos LA et al.: TACTICS (Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy)-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N. Engl. J. Med. 344(25), 1879-1887 (2001).
25. Lee DP, Niall HA, Hiatt BL et al.: Adjunctive platelet glycoprotein IIb/ IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (Tiger-PA) pilot trial. Circulation 107, 1479-1501 (2003).